An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
In brief
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Key facts
- Study ID
- NCT05732402
- Run by
- Alpine Immune Sciences, Inc.
- People needed
- 72
- Starts
- 2023-03-15
- Expected to finish
- 2028-03-02
- Last updated by the study team
- 2025-10-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigational Site (523) — Phoenix, Arizona, United States
- Investigational Site (501) — Phoenix, Arizona, United States
- Investigational Site (524) — Tucson, Arizona, United States
- Investigational Site (506) — Valencia, California, United States
- Investigational Site (513) — Arvada, Colorado, United States
- Investigational Site (512) — Orlando, Florida, United States
- Investigational Site (525) — Tamarac, Florida, United States
- Investigational Site (502) — Lawrenceville, Georgia, United States
- The Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
- Investigational Site (503) — Boston, Massachusetts, United States
- Washington University School of Medicine in St. Louis — St Louis, Missouri, United States
- Investigational Site (509) — Newark, New Jersey, United States
- Investigational Site (511) — Albany, New York, United States
- Investigational Site (508) — Brooklyn, New York, United States
- Investigational Site (518) — Bethlehem, Pennsylvania, United States
- Investigational Site (118) — Colleyville, Texas, United States
- Investigational Site (516) — Houston, Texas, United States
- Investigational Site (526) — Irving, Texas, United States
- Investigational Site (519) — Concord, New South Wales, Australia
- Investigational Site (515) — Saint Albans, Victoria, Australia
- Investigational Site (102) — Nedlands, Western Australia, Australia
- Investigational Site (191) — Caguas, Puerto Rico
- Investigational Site (507) — Cheonan, Chungcheongnam-do, South Korea
- Investigational Site (505) — Anyang-si, Gyeonggi-do, South Korea
- Investigational Site (504) — Goyang-si, Gyeonggi-do, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.